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AbsTrACT
Objective Sorafenib is the standard systemic therapy 
for advanced hepatocellular carcinoma (Hcc). Survival 
benefits of resection/local ablation for early Hcc are 
compromised by 70% 5-year recurrence rates. the phase 3 
StOrM trial comparing sorafenib with placebo as adjuvant 
treatment did not achieve its primary endpoint of improving 
recurrence-free survival (rFS). the biomarker companion 
study BiOStOrM aims to define (a) predictors of recurrence 
prevention with sorafenib and (B) prognostic factors with B 
level of evidence.
Design tumour tissue from 188 patients randomised 
to receive sorafenib (83) or placebo (105) in the StOrM 
trial was collected. analyses included gene expression 
profiling, targeted exome sequencing (19 known 
oncodrivers), immunohistochemistry (perK, pVegFr2, 
Ki67), fluorescence in situ hybridisation (VegFa) and 
immunome. a gene signature capturing improved rFS in 
sorafenib-treated patients was generated. all 70 rFS events 
were recurrences, thus time to recurrence equalled rFS. 
Predictive and prognostic value was assessed using cox 
regression models and interaction test.
results BiOStOrM recapitulates clinicopathological 
characteristics of StOrM. none of the biomarkers tested 
(related to angiogenesis and proliferation) or previously 
proposed gene signatures, or mutations predicted sorafenib 
benefit or recurrence. a newly generated 146-gene 
signature identifying 30% of patients captured benefit to 
sorafenib in terms of rFS (p of interaction=0.04). these 
sorafenib RFS responders were significantly enriched in 
cD4+ t, B and cytolytic natural killer cells, and lacked 
activated adaptive immune components. Hepatocytic perK 
(Hr=2.41; p=0.012) and microvascular invasion (Hr=2.09; 
p=0.017) were independent prognostic factors.
Conclusion in BiOStOrM, only hepatocytic perK and 
microvascular invasion predicted poor rFS. no mutation, 
gene amplification or previously proposed gene signatures 
predicted sorafenib benefit. a newly generated multigene 
signature associated with improved rFS on sorafenib 
warrants further validation.
Trial registration number nct00692770.
bACkgrOunD
Hepatocellular carcinoma (HCC) is the most 
common primary liver malignancy, with nearly 
850 000 new cases/year worldwide.1 At early stages 
of the disease, surgical resection, liver transplanta-
tion and local ablation are considered the main treat-
ments.2 However, up to 70% of patients treated with 
significance of this study
What is already known on this subject?
 ► There is no standard adjuvant treatment after 
resection/ablation for hepatocellular carcinoma 
and thus this is an unmet medical need. The 
phase 3 STORM study did not show benefits 
for sorafenib compared with placebo in terms 
of recurrence-free survival (RFS). In some solid 
tumours, however, cancer therapies based on 
predictive biomarkers assessed post hoc have 
entered clinical practice (eg, KRAS mutations 
status for cetuximab in colorectal cancer). We 
are herein reporting a level B evidence of a 
companion study of the phase 3 STORM trial 
exploring prognostic factors and predictors of 
response to sorafenib.
What are the new findings?
 ► In terms of prediction of response to sorafenib, 
none of the previously reported gene signatures 
or biomarkers (amplification VEGFA, pERK) 
were predictive to sorafenib efficacy. We 
have generated a new gene signature that is 
independent of whatever clinical-pathological 
variable and is able to discriminate patients 
who respond to sorafenib in terms of RFS. 
In terms of prognosis, we identified pERK 
and microvascular invasion as prognostic 
biomarkers of poor RFS. However, none of the 
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significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► The study confirms the lack of known biomarkers as 
predictors of response to sorafenib, and proposes a gene 
signature at level B evidence (Simon et al, 2009) that once 
validated might help at selecting patients able to benefit 
from sorafenib in the setting of adjuvancy.
resection or local ablation present tumour recurrence at 5 years.1 
Therefore, prevention of HCC recurrence—through the clearance 
of micrometastasis or de novo tumours by adjuvant treatments—
is a major unmet medical need. In the past decade, a significant 
improvement in the management of advanced HCC has occurred. 
Sorafenib was first approved a decade ago3, and more recently 
other therapies have shown clinical benefits and/or US Food and 
Drug Administration approval as first (lenvatinib)4 or second-line 
treatments (regorafenib5, cabozantinib6, nivolumab7 and ramu-
cirumab8). Sorafenib is an oral multikinase inhibitor targeting the 
mitogen-activated protein kinase/extracellular signal-regulated 
kinase (MAPK/ERK) pathway, vascular endothelial growth factor 
receptors (VEGFR) and KIT, among other targets,9 that provides 
nearly 3-month median survival benefit and a 31% reduction 
of risk of death in patients with advanced HCC.3 Regorafenib 
displays more potent pharmacological activity than sorafenib and 
provided a 38% reduction of risk of death in patients progressing 
on sorafenib treatment.5 10
Several randomised studies testing adjuvant therapies such as 
interferon (IFN), chemotherapy, chemoembolisation, internal 
radiation, immune therapies and retinoids have failed to provide 
outcome benefits or led to inconclusive results and therefore are not 
recommended in clinical practice.2 11 In this context, the STORM 
trial was designed to evaluate the efficacy and safety of sorafenib as 
an adjuvant therapy in patients with HCC with a complete radio-
logical response following surgical resection or local ablation.12 
This phase 3, randomised, double-blind, placebo controlled trial 
included 1114 patients. The primary endpoint of recurrence-free 
survival (RFS) was not met (33.3 months in the sorafenib group vs 
33.7 months in the placebo group; HR 0.94; 95% CI 0.78 to 1.13, 
p=0.26)12 and therefore further research is required to identify 
strategies to prevent HCC recurrence.
The mechanism of action of sorafenib includes inhibition of 
both MAPK/ERK-mediated cell proliferation and angiogenesis 
driven by VEGF signalling.9 Moreover, it is known that sorafenib 
acts both on tumour cells as well as on endothelial cells.9 Despite 
multiple studies, robust predictive biomarkers of response to 
sorafenib (including sorafenib targets such as MAPK/ERK or 
VEGF) in patients with HCC have not yet been identified. While 
sorafenib provides benefits across all subgroups of patients, a 
recent meta-analysis of individual data from the phase 3 SHARP 
and Asia-Pacific HCC trials showed that patients with HCV aeti-
ology and liver only disease have a significantly greater benefit 
with sorafenib.13 14 In terms of biomarkers, correlative analyses in 
the SHARP trial showed a non-significant trend towards higher 
survival benefit from sorafenib treatment in tumours with high 
c-Kit or low hepatocyte growth factor (HGF) plasma concentra-
tion.15 Nonetheless, no biomarker has been identified to clearly 
predict sorafenib efficacy. In this scenario, a thorough analysis 
of biomarker-defined subpopulations that might benefit from 
sorafenib in the adjuvant setting is required.
Herein we used a cohort derived from the phase 3 STORM trial 
population to conduct a companion biomarker analysis aimed at 
identifying biomarkers predicting sorafenib efficacy in preventing 
recurrence of HCC (hereafter, predictive biomarkers) and factors 
independently associated with prognosis (hereafter, prognostic 
biomarkers). Because our biomarker study was conducted on 
specimens collected in a randomised controlled trial (RCT) and 
were assayed after trial completion, our results hold a level B of 
evidence.16 This level of evidence goes beyond observational or 
retrospective biomarker studies (levels C and D) and is the closest 
to an RCT specifically designed to address tumour marker value as 
a predictor of outcome (level A).16
MATeriAls AnD MeTHODs
Tumour samples
Formalin-fixed paraffin-embedded (FFPE) tissue blocks 
from patients with HCC resected between 2008 and 2010 
and randomised into treatment in the STORM clinical trial 
(NCT00692770)12 were collected from the highest enrolling 
centres after ad hoc institutional review board clearance (online 
supplementary table 1). Out of the 202 collected samples, 188 
were suitable for the study (hereinafter, BIOSTORM cohort) 
(figure 1). See also online supplementary materials and methods.
immunohistochemistry, fluorescence in situ hybridisation, 
whole transcriptome analysis and targeted exome sequencing
See online supplementary materials and methods.
endpoints, clinical data and statistical analysis
RFS was defined as the time from randomisation to the first 
documented disease recurrence by independent radiological 
assessment or death by any cause, whichever happened first. The 
primary endpoint was to identify biomarkers predicting sorafenib 
efficacy in preventing HCC recurrence in terms of RFS. The 
secondary endpoint was to define prognostic biomarkers of RFS 
and/or validate those previously reported. In the BIOSTORM 
cohort, all events were recurrences (70 RFS events in 188 
patients), and thus time to progression was equivalent to RFS. 
Biomarkers were considered predictive of sorafenib efficacy in 
preventing HCC recurrence when p of interaction was <0.05. 
Patients who had undergone less than one treatment cycle (4 
weeks) were excluded from the predictive biomarker analysis 
(sorafenib: n=9 out of 83; placebo: n=6 out of 105). All statis-
tical tests were two sided. Data were analysed with SPSS V.23.0 
(SPSS) and the R statistical package. See also online supplemen-
tary materials and methods.
resulTs
baseline and clinical characteristics of the biOsTOrM cohort
The BIOSTORM cohort consists of a subgroup of 188 patients 
representing 21% of the 900 STORM patients who had been 
treated with surgical resection. From those, 83 had been treated 
with sorafenib and 105 with placebo. All baseline patient demo-
graphics and disease characteristics were balanced in both 
BIOSTORM treatment groups (table 1). In addition, most 
BIOSTORM clinical-pathologic characteristics were similar 
to the STORM cohort, which only differed in age (p<0.001), 
prevalence of hepatitis C (p<0.001) and microvascular invasion 
(p=0.003).
In BIOSTORM, as in STORM, median duration of treatment 
was shorter in sorafenib-treated patients compared with placebo 
(17 vs 30.6 months; p=0.007). Follow-up was shorter in 
sorafenib patients compared with placebo (30.9 vs 41.8 months; 
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Figure 1 Flow chart of the BIOSTORM study. FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; VEGFA, vascular endothelial 
growth factor A. 
p<0.001), partially due to a higher rate of treatment discon-
tinuation. In BIOSTORM, median RFS in placebo arm was 
42.0 months and was not reached with sorafenib. Moreover, no 
significant benefit of sorafenib on RFS was observed (HR=0.82; 
95% CI 0.50 to 1.35; p=0.430) (online supplementary figure 
1). This was consistent with the STORM subgroup analysis of 
patients undergoing resection (HR=0.94; 95% CI 0.76 to 1.16).
Molecular factors predicting benefit to sorafenib
None of the baseline clinical variables (summarised in table 1) 
such as microvascular invasion (p=0.164) or presence of satel-
lites (p=0.627) predicted response to sorafenib by p of interac-
tion test. Thus, we explored molecular variables from MAPK 
pathway, VEGF pathway and previously reported molecular 
signatures and drivers to assess their predictive capacity.
MAPK pathway
Given that sorafenib is a multikinase inhibitor that targets 
predominantly pathways involved in proliferation and neoan-
giogenesis, we sought to explore the predictive capability of 
different members of the MAPK pathway and VEGF signalling.
It is well known that the RAS/RAF/MAPK/ERK cascade plays a 
role in the regulation of cell proliferation, survival and differenti-
ation,17 and phosphorylated extracellular signal-regulated kinase 
(pERK) is a commonly used surrogate of MAPK pathway acti-
vation. In BIOSTORM, nuclear and cytoplasmic pERK staining 
was observed in tumour hepatocytes in 11% of the patients 
(n=20/175), whereas it was identified in 86% of patients in 
tumour-associated endothelial cells (n=150/175) (figure 2A,B). 
These results were consistent with our previous data.18 Tumours 
with positive pERK hepatocyte staining significantly correlated 
with the proliferative marker Ki67 (p=0.048) (online supple-
mentary figure 2). In terms of clinical-pathologic correlations, 
tumours displaying pERK hepatocyte staining were significantly 
associated with poorly differentiated tumours (p=0.002). In 
parallel, tumours with pERK-positive endothelial cells were 
smaller compared with pERK-negative cases (mean tumour size 
41 vs 60 mm; p=0.033). Samples with negative pERK endo-
thelial staining were positive for CD31 (online supplementary 
figure 2), suggesting that this negative staining was not due to 
absence of vascularisation.
To evaluate if pERK predicted RFS according to treatment 
allocation, we analysed the interaction between pERK and 
sorafenib effect. Sorafenib-treated patients with negative hepato-
cyte pERK staining (n=64/75, 85.3%) presented increased RFS 
compared with patients in the placebo group with negative 
hepatocyte pERK staining (median RFS not reached vs 42.1 
months; HR=0.49; p=0.043), a difference that was not signifi-
cantly better when compared with RFS of those patients with 
positive hepatocyte pERK staining (p of interaction p=0.11; 
online supplementary figure 3A). Neither endothelial pERK (p 
of interaction p=0.10; online supplementary figure 3B) nor Ki67 
(p of interaction p=0.19) was predictive of sorafenib efficacy in 
terms of RFS. Also, the predictive value of additional previously 
reported candidate biomarkers,15 such as expression levels of 
HGF, c-Kit, vascular endothelial growth factor A (VEGFA) and 
basic fibroblast growth factor/fibroblast growth factor 2 (bFGF/
FGF2) did not retain significant predictive value.
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Table 1 Baseline patient demographics and disease characteristics 
by treatment group within BIOSTORM and compared with the STORM 
population undergoing resection
biOsTOrM (n=188)
sTOrM (n=900)sorafenib (n=83) Placebo (n=105)
Age (years), median 
(range)
63 (34–82) 61 (26–84) 58 (19–83)
 ≥65 years, n (%)* 39 (47.0) 45 (42.9) 267 (29.7)
Sex, n (%)
  Male 74 (89.2) 92 (87.6) 743 (82.6)
  Female 9 (10.8) 13 (12.4) 157 (17.4)
Race, n (%)
  Asian 61 (73.5) 70 (66.7) 605 (67.2)
  White 20 (24.1) 34 (32.4) 255 (28.3)
  Other 2 (2.4) 1 (1.0) 40 (4.4)
Region, n (%)
  Americas (North, 
South)
6 (7.2) 8 (7.6) 102 (11.3)




56 (67.5) 68 (64.8) 574 (63.8)
  Europe 21 (25.3) 29 (27.6) 224 (24.9)
Aetiology, n (%)
  Hepatitis B only* 38 (45.8) 42 (40.0) 486 (54.0)
  Hepatitis C only* 24 (28.9) 37 (35.2) 177 (19.7)
  Alcohol only 5 (6.0) 6 (5.7) 61 (6.8)
  Unknown 15 (18.1) 13 (12.4) 120 (13.3)
  Other 1 (1.2) 7 (6.7) 56 (6.2)
BCLC stage, n (%)
  Very early stage 
(0)
6 (7.2) 8 (7.6)
  Early stage (A) 77 (92.8) 97 (92.4)
Number of lesions, n (%)
  1 73 (88.0) 99 (94.3) 851 (94.6)
  2 9 (10.8) 5 (4.8) 41 (4.6)
 ≥3 1 (1.2) 1 (1.0) 8 (0.9)
Maximum tumour 
size (mm), median 
(range)
39 (12–145) 35 (16–175) 40 (10–200)
Microscopic vascular invasion, n (%)†
  No 49 (59.0) 54 (51.4) 607 (67.4)
  Yes* 33 (39.8) 48 (45.7) 293 (32.6)
Tumour satellites, 
n (%)†
  No 77 (92.8) 96 (91.4) 819 (91.0)
  Yes 5 (6.0) 6 (5.7) 81 (9.0)
Histological grade, n (%)‡
  1 15 (18.1) 17 (16.2) 154 (17.1)
  2 53 (63.9) 67 (63.8) 576 (64.0)
  3 15 (18.1) 20 (19.0) 169 (18.8)
Risk of recurrence, 
n (%)†
  Intermediate 35 (42.2) 45 (42.9) 470 (52.2)
  High* 47 (56.6) 57 (54.3) 430 (47.8)
Months resection 
to random, median 
(range)§
1.8 (1.4–3.9) 1.8 (1.3–7.2) 2.6
Liver cirrhosis 
present, n (%)




sTOrM (n=900)sorafenib (n=83) Placebo (n=105)
  5 68 (81.9) 85 (81.0) 716 (79.6)
  6 14 (16.9) 19 (18.1) 161 (17.9)
  7 1 (1.2) 1 (1.0) 19 (2.1)
Albumin (g/dL), 
median (range)
4.0 (2.9–4.7) 4.0 (2.8–5.1) 3.9
Total bilirubin (mg/
dL), median (range)
0.5 (0.2–2) 0.6 (0.2–2.3) 0.6
AFP (ng/mL), median 
(range)
5.2 (1.8–313.6) 5.8 (1.3–239.7) 5.2
High risk of recurrence was considered if patients had either one tumour of 
any size plus microvascular invasion, satellite tumours, or poorly differentiated 
microscopic appearance, or two or three tumours each 3 cm or smaller in size. 
An intermediate risk was defined as a single tumour of 2 cm or larger with well-
differentiated or moderately differentiated microscopic appearance, and the 
absence of microvascular invasion or satellite tumours. Presence of liver cirrhosis 
was determined according to Case Report Form.
*P<0.05 for comparisons between patients in BIOSTORM and STORM cohorts.
†Not available in four patients in BIOSTORM.
‡Not available in one patient in BIOSTORM and STORM.
§Months diagnosis to randomisation in STORM trial.
¶Four patients in STORM trial had Child-Pugh 8. 
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer Group. 
Table 1 Continued
VEGF signalling
We had previously identified focal chromosomal amplifications 
in the locus of VEGFA—the gene encoding for the VEGFR2 acti-
vating ligand—in approximately 7% of patients with HCC, as 
the second most prevalent focal amplification in HCC.1 19 Retro-
spective studies have suggested that VEGFA gene copy number 
predicts response to sorafenib-treated patients in the adjuvant 
setting.20 Thus, we analysed whether pVEGFR2—a surrogate 
of the proliferative VEGF pathway—or VEGFA levels predicted 
RFS in sorafenib-treated patients.
Immunohistochemical analysis of pVEGFR2 revealed two 
different patterns of staining: nuclear pVEGFR2 staining, 
detected in tumour hepatocytes in 36% of the patients (n=54/152) 
(figure 2C,D), and cell membrane pVEGFR2 staining, detected 
only in 4% of the patients (n=6/152). Nuclear pVEGFR2 posi-
tively regulates the expression of the VEGFR2 gene itself by 
interacting with the promoter region of the gene, and promotes 
endothelial cell growth and proliferation.21 When tested for 
interaction with the treatment, absence of nuclear pVEGFR2 
staining presented a non-significant trend for better RFS with 
sorafenib (p of interaction p=0.083) (online supplementary 
figure 3C). Membrane pVEGFR2 was not tested because of the 
limited number of samples displaying this staining.
On the other hand, analysis of VEGFA copy number demon-
strated that high-level gains of this gene (≥4 copies) were 
present in 10% of the patients (n=17/162) (figure 2E,F), consis-
tent with our previous observations.19 Nonetheless, high-level 
gains of VEGFA did not correlate with recurrence prevention 
in sorafenib-treated patients (p of interaction p=0.938) (online 
supplementary figure 3D). Tumours with satellites (p<0.001) 
and microvascular invasion (p=0.019) were significantly 
enriched with VEGFA focal amplifications.
Reported molecular signatures and driver genes
To further investigate candidate predictive biomarkers, we anal-
ysed whole-genome expression. We obtained transcriptomic 
data for 140 HCC samples and 90 non-tumour adjacent tissues. 
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Figure 2 Representative examples of (A) immunohistochemical pERK staining of tumour hepatocytes, (B) pERK staining of tumour endothelial cells, 
and (C, D) pVEGFR2 positive and negative staining of tumour hepatocytes. (E, F) Representative images of fluorescence in situ hybridisation (FISH) 
staining to determine vascular endothelial growth factor A (VEGFA) copy number. VEGFA was labelled in red; the control reference Cep6 in green; and 
DAPI-stained cell nuclei in blue.
The transcriptomic profile of each sample was used to classify 
each tumour according to its molecular class, and to assess 
enrichment of signalling pathways, progenitor features and clin-
ical characteristics. Around 40% of the patients belong to the 
proliferation subclass19 (n=53/140) (online supplementary table 
2), as observed in other HCC cohorts. This group of tumours 
was significantly enriched in S1 subclass (p<0.001),22 aberrant 
activation of tyrosine-protein kinase Met or hepatocyte growth 
factor receptor (MET)23 (p=0.038), late transforming growth 
factor beta (TGFβ)24 (p=0.009), insulin-like growth factor 1 
receptor (IGF1R)25 (p<0.001), Notch26 (p<0.001), mechanistic 
target of rapamycin (mTOR)27 (p<0.001), and gene signatures 
associated with recurrence28 (p=0.015), vascular invasion29 
(p<0.001) and sorafenib resistance30 (p=0.002). Of note, 
tumours displaying pERK-positive hepatocytes were enriched 
in proliferation-related signatures (IGF1R25 (p<0.001), Notch26 
(p<0.001), Cytokeratin 19 (CK19)31 (p=0.015) and G232 
(p=0.004)) (online supplementary table 3). On the other hand, 
patients in the non-proliferation class19 (45%, n=63/140) were 
significantly associated with S3 subclass22 (p<0.001).
In terms of prediction, we tested 22 previously reported 
tumour-derived molecular signatures, and survival prog-
nostic signatures generated from adjacent non-tumour samples 
capturing the microenvironment signalling (online supplemen-
tary table 2).31 33 34 None of them showed predictive capacity 
in terms of RFS (equivalent to recurrence) in the interaction 
analysis. This applies to signatures designed for/or associated to 
recurrence24 28 32 or survival33 34 in retrospective analysis. Finally, 
the prognostic capacity of survival of gene signatures was not 
tested due to the marginal number of events (24/188).
Further, we explored the mutational landscape of the 
BIOSTORM cohort using targeted exome sequencing to iden-
tify mutations in 19 known HCC drivers1 (online supplementary 
table 4; online supplementary figure 4). The mutational profile 
was similar to what has been previously reported for HCC 
drivers,1 with TERT promoter mutations (53%), TP53 (46%), 
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Figure 3 Novel 146-gene signature associated with better recurrence-free survival (RFS) in sorafenib-treated patients. (A) 146-gene signature 
identifying BIOSTORM patients with better RFS when treated with sorafenib. (B) Kaplan-Meier estimates measuring RFS probability over time of 
patients identified by the 146-gene signature capturing recurrence prevention in individuals treated with sorafenib (in blue) or placebo (in orange). P 
value of biomarker treatment interaction was 0.040. Left panel shows the Kaplan-Meier estimates for patients identified as ‘sorafenib RFS responders’ 
by the gene signature, and the right panel, the estimates for those identified as ‘non-responders’. (C) Patients identified by the 146-gene signature as 
‘sorafenib RFS responders’ (in green) displayed downregulation of KRAS and JAK/STAT signalling. In contrast, patients recognised as ‘non-responders’ 
(in red) were enriched in MAPK, mTOR, IGF1R and Notch signalling.
CTNNB1 (21%) and AXIN1 (16%) as the four most prevalent 
mutations in our cohort (online supplementary table 4). No 
significant association was found between mutational profile and 
outcome in terms of RFS and treatment.
novel 146-gene expression signature predicts role of 
sorafenib in prevention of recurrence
Given the lack of interaction between tested clinical and 
biomarker candidates and treatment benefit, we developed a 
gene expression signature able to predict the role of sorafenib in 
recurrence prevention of HCC in resected patients.
Using standard procedures, we first identified genes associ-
ated with prognosis (Cox score p<0.05) in terms of RFS in the 
set of 67 sorafenib-treated patients and in the set of 73 place-
bo-treated patients (figure 1). To exclude genes that were mainly 
associated with poor prognosis independently of treatment, we 
filtered out those genes identified with the same prognosis value 
in both cohorts, keeping only those exclusively detected in the 
sorafenib group. We obtained a 146-gene set able to discriminate 
precisely patients benefiting from sorafenib in terms of extended 
RFS (from herein referred to as ‘sorafenib RFS responders’) 
from patients where sorafenib had no effect (‘non-responders’) 
(figure 3). This gene signature was composed of 87 poor 
prognosis genes and 59 good prognosis genes (figure 3A and 
online supplementary table 5). The signature identified 30% of 
the patients (n=42/140) as ‘sorafenib RFS responders’. These 
patients did not reach median RFS with sorafenib, while ‘non-re-
sponders’ presented a median RFS of 28 months. The predictive 
value of the signature was statistically significant (p of interac-
tion p=0.040) in the BIOSTORM cohort (figure 3B).
We characterised ‘sorafenib RFS responders’ and ‘non-re-
sponders’ at the molecular level using enrichment analysis tools 
(figure 3C). In brief, ‘sorafenib RFS responders’ showed (A) 
downregulation of pathways indicative of poor prognosis such 
as KRAS, (B) activation of EIF2 signalling—previously reported 
to be inhibited after sorafenib treatment9—and oxidative stress 
responses, (C) association with immune-related processes, 
such as T helper cell differentiation and B cell development, 
and (D) upregulation of bile acid and lipid metabolism-related 
pathways (ie, liver X receptor signalling and related farnesoid 
X receptor/retinoid X receptor) (online supplementary tables 
6–8). All these molecular traits were also present in the non-tu-
mour adjacent tissue (online supplementary tables 7 and 8). 
Conversely, ‘non-responders’ (98/140; 70%) were characterised 
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Figure 4 Heatmap displaying the molecular class and immune characteristics of ‘sorafenib RFS responders’ and ‘non-responders’. Differences in 
RFS profiles in the sorafenib and placebo-treated patients identified by the signature as ‘sorafenib RFS responders’ suggest that placebo patients 
could have been candidates to respond to sorafenib. Immune profile of ‘sorafenib RFS responders’ highlights absence of CD8+ T cell lymphocytes but 
enrichment of other adaptive immune elements such as B cells and CD4+ T cells and derivatives. P values describe differences between ‘sorafenib 
RFS responders’ and ‘non-responders’. #P<0.01 between ‘sorafenib RFS responders’ and HCCs of ‘Immune class’. Signatures are referenced in online 
supplementary table 11. HCC, hepatocellular carcinoma; IFN, interferon; MHC, major histocompatibility complex; NK, natural killer cells; ns, non-
significant differences; RFS, recurrence-free survival; TLS, tertiary lymphoid structures. 
by (A) activation of signalling pathways of poor outcome (PI3K-
AKT-mTOR, KRAS, MAPK, IGF1R, Notch); (B) higher mRNA 
alpha-fetoprotein levels (p=0.03); and (C) microvascular inva-
sion (p=0.042) and HCV-related HCC (p<0.001) (figure 3C, 
online supplementary figure 5C and online supplementary tables 
6–9). Of note, the mutational profile of known oncogenes in 
HCC was not significantly different in ‘sorafenib RFS responders’ 
when compared with ‘non-responders’.
immune cell profiles in ‘sorafenib rFs responders’
Recent preclinical studies have suggested that sorafenib may 
exert immune-modulating effects on the tumour microenviron-
ment of HCC through upregulation of T cell activity, inhibition 
of macrophage-induced tumour growth and activation of natural 
killer (NK) cells.35–37 Therefore, it is important to understand the 
immune profile of ‘sorafenib RFS responders’ tumours. To this 
end, we characterised the immune infiltrates of the BIOSTORM 
tumours using published gene signatures38 and data decon-
volution methods (ie, Cibersort),39 and correlated the results 
with the prediction of the 146-gene signature and our recently 
reported HCC Immune class.38 In this regard, we have defined 
that ~30% of HCCs present an ‘inflamed’ microenvironment 
(so-called Immune class) with high infiltration of immune cells, 
adaptive T cell response, active IFN-γ signalling and markers of 
cytolytic activity.38 The Immune class did not directly predict 
recurrence or response to sorafenib.
Here, our results indicate that the immune profile of ‘sorafenib 
RFS responder’ patients (n=42/140, 30%) was characterised by 
enrichment of signatures capturing the presence of B cells and 
CD4+ T cells and derivatives (type 1 and 2 T helper cells, and 
follicular helper T cells); and the exclusion of Immune class-as-
sociated features (ie, CD8+ T cells, effector memory T cells, and 
central memory T cells and tumour-associated tertiary lymphoid 
structures (TLS), generated during chronic immune stimulation 
to support infiltration and activation of the adaptive immune 
cells) (figure 4). Furthermore, the innate immune profile of 
‘sorafenib RFS responders’ was enriched in activated Mast cells 
and cytolytic NK cells (NKCD56dim), and showed absence of acti-
vated macrophages, components from the major histocompat-
ibility complex, and downregulation of signal transducer and 
activator of transcription proteins and focal adhesion kinase 
1/protein tyrosine kinase 2 (FAK1/PTK2) (figure 4, online 
supplementary figures 5 and 6).39 In addition, ‘sorafenib RFS 
responders’ had significantly lower immunophenoscore—which 
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Figure 5 Prognostic value of hepatocyte pERK and pVEGFR2. Tumours with hepatocyte pERK staining (A) or pVEGFR2 staining (B) have significantly 
poorer outcome compared with pERK negative or pVEGFR2 tumours.
Table 2 Univariate and multivariate analysis of clinical and molecular prognostic factors in terms of RFS
Patients (%)
univariate Multivariate
Hr (95% Ci) P values Hr (95% Ci) P values
Liver cirrhosis (present vs absent) 106 (56) 1.64 (1.00 to 2.69) 0.049 NS
Microscopic vascular invasion (yes vs no) 81 (44) 1.87 (1.16 to 3.00) 0.010 2.09 (1.14 to 3.83) 0.017
Aetiology (hepatitis C vs others) 61 (32) 1.70 (1.06 to 2.73) 0.028 NS
Hepatocyte pERK (positive vs negative) 20 (11) 2.46 (1.36 to 4.44) 0.003 2.41 (1.21 to 4.80) 0.012
pVEGFR2 (positive vs negative) 54 (36) 1.84 (1.09 to 3.09) 0.022 NS
G3 (present vs absent) 43 (31) 1.73 (1.00 to 3.00) 0.049 NS
MET (present vs absent) 18 (13) 2.28 (1.16 to 4.47) 0.017 NS
Response to IFNα1 (present vs absent) 24 (17) 2.09 (1.13 to 3.87) 0.019 NS
The univariate analysis was conducted for 33 variables, including clinicopathological variables (liver cirrhosis, microscopic vascular invasion, aetiology, multinodularity, maximum 
tumour size (threshold 50 mm), tumour satellites, histological grade (3 vs 1–2)), molecular traits (hepatocyte pERK, endothelial pERK, nuclear pVEGFR2 and VEGFA) and 22 gene 
signatures (online supplementary table 10). In the multivariate analysis, only microscopic vascular invasion and hepatocyte pERK retained independent prognostic value.
IFN, interferon; NS, non-significant; RFS, recurrence-free survival; VEGFA, vascular endothelial growth factor A. 
has been associated with response to checkpoint blockade—and 
downregulation of IFN gene signatures predicting response to 
checkpoint inhibitors in other cancers (figure 4).39–41
On the other hand, ‘non-responders’ (98/140; 70%) encom-
passed a subgroup of HCCs imprinted with Immune class 
traits (27/98; 28%), characterised by CD8+ T cells, TLS and 
programmed cell death protein 1 (PD1) signalling, along with 
another subgroup of HCCs characterised by Immune exclusion 
(CTNNB1 class: 27/98; 28%)38 (figure 4).
Prognostic biomarkers of HCC recurrence
The second aim of the study was to assess the prognostic value 
in terms of RFS of all above described clinical and molecular 
features. In the univariate analyses, positive hepatocyte pERK 
(HR=2.46; p=0.003) and nuclear pVEGFR2 (HR=1.84; 
p=0.022) were significantly associated with poor RFS (figure 5). 
In addition, three gene signatures (G332 enriched in cell cycle 
control genes (HR=1.73; p=0.049); MET23 (HR=2.28; 
p=0.017); and IFN1α42 (HR=2.09; p=0.019)) were associ-
ated with poor RFS (table 2 and online supplementary table 10). 
Previously reported gene signatures from tumour and adjacent 
tissue designed to predict survival33 34 or recurrence24 28 32 did 
not predict RFS in the current study (online supplementary table 
10). In the multivariate model, only hepatocyte pERK staining 
and microvascular invasion retained independent prognostic 
value for RFS (table 2). Both biomarkers were associated with 
poor prognosis (pERK HR=2.41; 95% CI 1.21 to 4.80; vascular 
invasion HR=2.09; 95% CI 1.14 to 3.83).
DisCussiOn
The success of sorafenib to inhibit tumour cell proliferation 
and angiogenesis43 and its proven efficacy in advanced HCC3 
provided the rationale for testing this compound as adjuvant 
therapy to prevent recurrence after resection or local ablation. 
The phase 3 trial did not achieve the primary endpoint of supe-
riority in RFS comparing sorafenib vs placebo. In the companion 
BIOSTORM study presented here, we explored biomarkers 
predicting the efficacy of sorafenib in preventing HCC recur-
rence, along with prognostic markers. Neither the proliferation 
or angiogenic biomarkers tested, nor the reported prognostic 
gene signatures or mutations identified in driver genes were 
associated with improved RFS in the sorafenib arm. The fact that 
none of the tested biomarkers predicted sorafenib RFS under-
scores the complexity of the mechanisms of action related to this 
drug. We generated a 146-gene signature able to identify 30% of 
patients who might benefit from sorafenib in terms of recurrence  on N
ovem
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prevention. In addition, we further confirmed the role of pERK 
and microvascular invasion as two independent predictors of 
recurrence in early HCC. Previously reported gene signatures 
from tumour and adjacent tissue designed to predict survival33 34 
or recurrence24 28 32 did not predict RFS in the current study. Our 
results hold a B level of evidence, which is based on subgroup 
or retrospective analysis of prospective phase 3 investigations.16
Thus far, more than 20 predictive biomarkers have entered 
clinical practice (eg, Her-2/neu expression as biomarker of 
response to trastuzumab; KRAS mutations for resistance 
to cetuximab or panitumumab).44–46 For sorafenib, vali-
dated biomarkers of response have not yet been identified. A 
companion study of the SHARP trial described that plasma 
concentrations of soluble c-Kit and HGF showed a non-signif-
icant trend towards predicting response to sorafenib.15 Several 
studies have proposed pERK, proxy of activation for the RAS/
MAPK pathway inhibited by sorafenib in vitro and in solid 
tumours,9 as a candidate biomarker associated to outcome after 
sorafenib treatment, though with contradictory results.47–49 The 
absence of a validated scoring system for immunostaining for 
pERK, and the differences in detection methods, cohorts and 
endpoints could account for these inconsistencies. On the other 
hand, VEGF-related biomarkers have been proposed as poten-
tial predictors of response to sorafenib, considering that this 
drug inhibits pVEGFR2.43 In this sense, VEGFA amplification 
was reported as a predictive factor of recurrence prevention in 
patients treated with sorafenib after liver resection.20 However, 
all the above studies claiming the predictive value of pERK or 
VEGF-related molecules have been tested in the setting of retro-
spective non-randomised studies.
In BIOSTORM, neither pERK, nor pVEGFR2 or VEGFA 
copy number status was significantly associated with recurrence 
prevention of sorafenib. Only sorafenib-treated patients tended 
towards better outcome if their tumours were hepatocyte-pERK 
negative and/or endothelial-pERK positive. Similarly, previ-
ously reported tumour-derived signatures associated with poor 
outcome in terms of recurrence or survival did not show predic-
tive capacity for RFS on interaction analysis.
Our generated signature identifying patients benefiting from 
sorafenib adjuvancy in terms of recurrence prevention classi-
fied 30% of cases as ‘sorafenib RFS responders’. These displayed 
downregulation of poor prognosis oncogenic pathways and 
deregulation of bile acid/lipid metabolism-related signalling, 
were enriched in B cells and CD4+ T cells (and derivatives) 
and presented exclusion immune features related to the HCC 
Immune class,38 and were associated to signatures of poor 
response to immune checkpoint inhibitors.39 41 On the other 
hand, ‘non-responders’ tumours presented traits of cancer 
aggressiveness, with more vascular invasion and activation of 
poor prognosis signalling cascades, among others. The fact that 
HCV was more prevalent in non-responders does not align well 
with our previous report where HCV-related HCC had a better 
response to sorafenib in advanced cases.14 Thus, clarification of 
this association would require further research.
In terms of prognostic biomarkers, here we report pERK 
staining and microvascular invasion as two independent predic-
tors of RFS in early HCC. While microvascular invasion is a 
well-established predictor of recurrence, the role of pERK is less 
documented. In our hands, patients displaying tumour pERK 
hepatocyte staining were characterised by poor differentiation 
degree and enhanced proliferation traits. pERK is a key element 
in angiogenesis and apoptosis. Nuclear pERK has been involved 
in proliferation processes, and the cytoplasmic form in cell 
differentiation. In the setting of early HCC, only one previous 
retrospective study reported a correlation between ERK activa-
tion and poor survival.50 In terms of prognostic value of gene 
signatures, the univariate analysis revealed that three gene signa-
tures (G3,32 MET,23 IFN1α42) predicted poor RFS, whereas 
previously reported gene signatures from tumour and adja-
cent tissue designed to predict survival33 34 or recurrence24 28 32 
were not significantly associated with RFS. None of the above 
described signatures retained independent prognostic value in 
the multivariate analysis.
Lastly, we acknowledge the strengths and limitations of the 
study. A major strength is that the study was conducted with a 
subgroup of patients randomised in the setting of the phase 3 
STORM trial.12 Therefore, BIOSTORM patients were prospec-
tively followed, and management of adverse events, drug 
prescriptions and patients’ outcomes were properly scrutinised. 
In addition, the primary endpoint RFS (which in BIOSTORM 
study overlaps with time to recurrence) was assessed by central 
radiological reviewers. Finally, we used FFPE samples (stan-
dardised method of tissue processing) to ensure the highest 
preanalytical validity and followed standardised scoring criteria 
or, when absent, published criteria to ensure analytical validity. 
All these positive factors contrast with the conventional retro-
spective nature of most biomarker studies.51 Moreover, our 
study follows the Reporting Recommendations for Tumor 
Marker guidelines,52 and together with the SHARP biomarker 
investigation15 is one of the few HCC studies for biomarker 
discovery with level B of evidence16 (meaning retrospective 
study conducted in the setting of a randomised phase 3 trial). 
These types of studies have changed the standard of care in cases 
where the primary endpoint was negative, but the biomarker 
companion investigation yields positive results. This is the case 
of cetuximab for patients with colorectal cancer with wild-type 
RAS.45 In terms of limitations, we acknowledge that despite a 
huge collecting effort, the number of patients recruited (n=188) 
is not ideal for defining bona fide predictive biomarkers.16 This 
fact reinforces the need of budget allocation for ensuring the 
collection of tissue samples in the setting of controlled investi-
gations in HCC.
Overall, our biomarker BIOSTORM study (A) established lack 
of predictive value of sorafenib response for previously reported 
molecular biomarkers, (B) generated a predictive 146-gene 
signature to discriminate patients where sorafenib would 
prevent recurrence after resection, (C) established pERK and 
microvascular invasion as independent prognostic tools to iden-
tify recurrences in patients resected from early HCC tumours, 
and (D) did not validate previously reported signatures associ-
ated with recurrence.24 28 32 For any of these biomarkers to be 
used as surrogates of efficacy of sorafenib recurrence prevention, 
a validation study using an independent cohort and conducted 
by independent investigators would be required.
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